Medtronic urology approval
This article was originally published in The Gray Sheet
Executive Summary
Firm announces FDA approval of its Interstim II system July 5. The implantable device uses sacral nerve stimulation to treat chronic, intractable cases of overactive bladder and urinary retention. According to Medtronic, the next-generation device is nearly half the size and weight of its predecessor. In May, the firm announced plans to pursue a pivotal trial for Interstim within the next year to establish better clinical evidence for the device's use...